15/11/2013 · Bendamustine and rituximab BR are synergistic in vitro, with rituximab increasing malignant cell sensitivity to bendamustine 14–16. BR has been used effectively for untreated or relapsed and refractory CLL 17–19, indolent NHL and mantle cell. Em detalhes, a bendamustina foi associada a uma mortalidade aumentada e a um perfil de segurança desfavorável quando utilizada em associação com rituximabe - comparada à quimioterapia padrão com rituximabe rituximabeciclofosfamida, doxorrubicina, vincristina e prednisona R-CHOP ou rituxima beciclofosfamida, vincristina e prednisona. 02/05/2018 · The combination of bendamustine Treanda and rituximab Rituxan induced a 12-month progression-free survival PFS of 78.6% for patients with chronic lymphocytic leukemia CLL, suggesting that the combination is an effective first salvage.

04/12/2018 · HealthDay News — For older patients with untreated chronic lymphocytic leukemia CLL, treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab, according to a study published online December 1 in the New England Journal of Medicine. 03/05/2016 · Because only 3 prospective clinical trials have demonstrated the efficacy and safety of bendamustine plus rituximab in previously untreated patients with CLL, researchers sought to evaluate the safety and efficacy of the chemoimmunotherapy regimen in a large cohort of patients in a “real-life” experience study.

Rituximab Premedication to be administered before all infusions: Paracetamol 1000mg po 60 minutes before rituximab Chlorphenamine 10mg IV 15 minutes before rituximab Dexamethasone 8mg IV 15 minutes before rituximab Other Drugs: Allopurinol 300mg po daily, ideally starting 24 hours before treatment - review after 4 weeks. 10/09/2012 · Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia:. CLL. PATIENTS AND METHODS: In all, 117 patients, age 34 to 78 years, 46.2% of patients at Binet stage C, and 25.6% of patients age 70 years or older received BR chemoimmunotherapy for first-line treatment of CLL. A Bendamustina substância ativa é um agente antitumoral alquilante com atividade única, contendo um anel benzimidazol do tipo purina. O efeito antineoplásico e citocida da Bendamustina substância ativa é baseado, essencialmente, em uma ligação cruzada das fitas simples e.